ABANZA, a pioneer in advanced soft tissue repair solutions, has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its WasherCap™ Mini fixation system.
This innovative device is designed for a range of orthopaedic procedures, including meniscal root repair and anterior cruciate ligament (ACL) reconstruction.
The WasherCap™ Mini is the first fixation system to provide surgeons with a knotless, bidirectionally tension-adjustable solution, ensuring secure fixation regardless of bone quality.
Biomechanical testing has demonstrated its superior strength and minimal displacement during cyclic loading, outperforming conventional options such as cortical buttons and suture anchors.
As the first FDA-cleared device of its kind, the WasherCap™ Mini is set to enhance surgical precision and improve patient outcomes.
This device offers surgeons a highly reliable solution for suture and tape fixation, particularly in procedures requiring precise tension control.
For meniscal root repair, its knotless technology addresses meniscal extrusion and restores the meniscus to its natural position, which we anticipate will lead to improved short- and long-term results while potentially slowing the progression of arthritis.
The WasherCap™ Mini is the latest addition to ABANZA’s portfolio of disruptive soft tissue repair technologies.
Future innovations, including the WasherCap™ In Line and LoopCap™, will further expand the company’s offering, delivering advanced solutions for procedures such as biceps tenodesis, medial collateral ligament repairs, and complex foot and ankle conditions.
